by The Postpartum Depression Drug market is estimated to be valued at US$ 5.115 Billion In 2022 and is expected to exhibit a CAGR of 30.25% over the forecast period 2022-2029, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Postpartum depression is one of the most common medical issues associated with childbirth that occurs in women after delivery. Postpartum depression affects both the woman and her newborn. The signs and symptoms of postpartum depression includes sadness, feelings of worthlessness, irritability, excessive crying, withdrawing from family and friends, changes in appetite, restlessness, fatigue, problems concentrating, and thoughts of suicide. To address the growing prevalence of postpartum depression, pharmaceutical companies are developing selective serotonin reuptake inhibitor (SSRIs) drugs to treat postpartum depression.
Market Dynamics:
The postpartum depression drug market growth is primarily driven by increasing awareness about postpartum depression and strong product pipeline. According to a study by the U.S. Centers for Disease Control (CDC), around 1 in 8 women experience postpartum depression after delivery in the U.S. The increasing awareness regarding postpartum depression among women through healthcare providers and social media platforms is helping them recognize the signs and seek timely medical help. Furthermore, several pharmaceutical companies are focusing on developing novel postpartum depression drugs. For instance, Sage Therapeutics is developing zuranolone (SAGE-217/ brexanolone), a next-generation positive allosteric modulator of GABAA receptors, for treatment-resistant postpartum depression. If approved zuranolone could become the first FDA approved drug for treatment-resistant postpartum depression.
Segment Analysis
The global Postpartum Depression Drug Market is segmented on the basis of drug class, end-user, and geography. Based on drug class, the market is divided into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others. Among these, the SSRIs segment holds the largest share of the market and is expected to dominate the segment over the forecast period. SSRIs are the first line of treatment for postpartum depression as they are more effective and have lesser side effects than other antidepressants.
PEST Analysis
Political: Regulations regarding the timely diagnosis and treatment of postpartum depression are being introduced in various countries which is supporting the market growth.
Economic: Rising healthcare expenditure and growing awareness about mental health is fueling the demand for postpartum depression treatment drugs in developing nations.
Social: Growing social support through nonprofit organizations and reducing stigma around mental illness is encouraging more women to seek treatment.
Technological: Advances in drug delivery systems and development of novel treatment options are expanding growth opportunities in the market.
Key Takeaways
The global postpartum depression drug market is expected to witness high growth, exhibiting CAGR of 30.25% over the forecast period, due to increasing awareness regarding mental health issues and de-stigmatization of postpartum depression.
The North American region dominates the global market owing to high incidence of postpartum depression cases and rapid introduction of novel treatment options in the region. According to estimates, 1 in 7 women in the U.S. experience postpartum depression symptoms.
Key players operating in the postpartum depression market are Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd. Major players are focusing on new product launches and geographical expansion to strengthen their market position.
In June 2021, Pfizer Inc. announced positive top-line results from the Phase 3 study evaluating its investigational medicine, zuranolone in adults with postpartum depression. The study met its primary endpoint demonstrating statistically significant improvement of symptoms compared to placebo.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
